Abbott Laboratories

**Official Title of the Study:** Abbott Laboratories Alinity s Blood Screening Assays – Clinical Evaluation Protocol

**NCT Number:** NCT03285295

**Type of Document:** Informed Consent Form: Alinity s Follow-Up Study – Donor Consent for Central IRB

**Date of Document:** August 17, 2017
Informed Consent Form
For Follow-up Specimens

TITLE: Abbott Laboratories Alinity s Blood Screening Assays – Clinical Evaluation

PROTOCOL NO.: 9DY-02-14U01-03
WIRB® Protocol #20170871

SPONSOR: Abbott Laboratories

INVESTIGATOR: Name
Address
City, State Zip
Country

STUDY-RELATED PHONE NUMBER(S): Name
(24 Hour Phone Number)

In this consent form, “you” always refers to the subject. If you are a parent or guardian, please remember that “you” refers to the study subject.

Introduction

Before agreeing to participate in this research study, it is important that you read and understand the following explanation of the proposed procedures. This document describes the purpose, procedures, benefits, and risks of the study.

The study is being conducted for and funded by Abbott Laboratories. Up to 23,000 – 90,000 individuals from several blood collection centers across the United States may be participating in the study associated with this follow-up blood draw.

Why is this research being done?

The purpose of this part of the study is to obtain an additional blood sample that may help interpret and better understand the investigational (research) test results of your previous specimen. The sample is to be used by Abbott to evaluate new investigational products (Alinity s blood screening assays) that detect Hepatitis B, Hepatitis C, HIV and HTLV viruses and Chagas disease in donor blood. An investigational product is one that is not approved by the United States Food and Drug Administration (FDA).
The potential implications for donation include notification and counseling, and may result in temporary or permanent deferral from donating blood/plasma in the future.

State law requires that the results of positive tests for HIV or hepatitis be reported to a local health agency.

**What will happen if I take part in this study?**

Your participation in this part of the study involves collection of a blood specimen.

If you choose to participate, no more than 20 mLs - 60 mLs (about 2-4 tablespoons) of blood will be collected by routine venipuncture. Your participation will require approximately 30 minutes of your time. No medication or treatment will be given as part of this research study.

**What alternative choices do I have?**

This study is for research purposes only. The only alternative is to not participate in this study.

**What are the possible risks involved with this study?**

Drawing blood may cause pain, bruising, lightheadedness, and, on rare occasions, infection at the site of the blood draw. The study poses no special risk to pregnant women or to an unborn fetus. There is a small risk of loss of confidentiality.

**What are the possible benefits of taking part in this study?**

This study is for research purposes only. You will not directly benefit from your participation in this study. Information from this study will be used to help others in the future by providing a better understanding of blood screening tests for Hepatitis B, Hepatitis C, HIV, HTLV and Chagas disease.

**What are the costs or payments for participating in this study?**

There will be no costs to you for your participation in this study. [If the subject will be paid You will be paid $[Amount] for your time involved in the study.] [If the subject will not be paid You will not be paid for your participation in the study.]

**Data We Collect From You:**

Your personal health information including data resulting from your participation in this research will be collected during the course of this study. Your personal health information includes results of any blood testing done by the donor facility or Abbott Laboratories.
How Your Data Will Appear:

Your identity and contact details will not be disclosed unless required by law. Rather, your identity and contact details will be replaced by a code, such as a number.

Why We Collect This Data:

Your personal health information will be used for clinical research and also for seeking approval from regulatory authorities to market the studied Alinity’s blood screening assays. It may also be used in study reports or for scientific presentations, but in a way that will not identify you by name. Your personal health information will be kept as confidential as possible and, unless required by law, will not be made publicly available. After this study has been completed, it is possible that your coded health information will be used for future research.

Who Will See Your Data:

The only people with access to your personal health information in identifiable form will be the [investigator], personnel helping [investigator] conduct the study at the facility, sponsor representatives who are checking that the study is conducted properly, and regulatory authorities where required by law.

By signing this document you are allowing the [investigator] and personnel at the facility to permit Abbott to have access to your personal health information for the purpose of collecting data, verifying the data is correct, and checking that the study is conducted properly.

In order to complete the research, Abbott, the [investigator] and personnel at the facility, the ethics committee(s) and domestic and foreign regulatory authorities responsible for overseeing research studies (including the U.S. Food & Drug Administration (FDA), U.S. Department of Health and Human Services, and/or equivalent government agencies in other countries) will have access to your coded health information.

Additionally, your personal health information may no longer be protected by HIPAA (Health Insurance Portability and Accountability Act) once it is disclosed to Abbott by the [investigator]. However, Abbott will take reasonable measures to keep your personal health information confidential. Unless withdrawn, your HIPAA authorization has no expiration date (except in the states of Washington, Indiana, or California, where it expires 50 years from the time you sign this form), since information collected for research purposes continues to be analyzed for many years.

Taking Back Your Permission to Use or Disclose Your Personal Health Information:

To take back your permission to use or disclose your personal health information you must write to: [insert name and address]. If you do this, you will no longer be allowed to be in this study. Any information that has already been collected at the time you take back your permission will
be kept and, where the law allows, your personal health information, will continue to be used by the [investigator] or Abbott or other parties involved with the study.

**Rights to Your Data:**

You may have the right to access, correct and make a copy of your clinical study records as allowed by applicable privacy laws. You may ask to see your records by requesting such records from the [investigator] or the facility(ies) where the study is being conducted. However, to ensure the valid results of the study, you agree that you may not be able to review or make a copy of some of your records related to the study until after the study has been completed.

When you sign this document, you agree to the access, collection, processing and transfer of your personal health information as described in this informed consent document. If you do not sign this document, you may not participate in the research study.

**Trial Registration**

A description of this clinical trial will be available on [http://www.ClinicalTrials.gov](http://www.ClinicalTrials.gov), as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.

**What if I become injured participating in this study?**

If during the course of the study any injury occurs to you as a direct result of your participation in this study, Abbott agrees to pay all reasonable medical expenses necessary to treat such injury, provided: (i) you have followed the directions of the investigators; and (ii) to the extent you are not otherwise reimbursed by medical insurance. Contact the study staff at the number listed on the first page of this document to find out where to go to obtain treatment.

**Is my participation in the study voluntary?**

Your participation in the study is voluntary. You may decide not to participate or discontinue participation at any time without penalty or loss of benefits to which you are otherwise entitled.

**Can I withdraw from the study at any time?**

You may choose not to participate, or to withdraw from the study at any time without any penalty or loss of benefits to which you are entitled. However, information collected prior to your withdrawal may still be used or disclosed after your withdrawal.

The investigator or Abbott may remove you from the study without your consent for any of the following reasons: if it appears to be medically harmful to you, if it is discovered that you do not meet the study requirements, at the discretion of the investigator, or if the study is canceled.
**Whom do I contact if I have questions or concerns about the study?**

During the study, if you experience any medical problems, suffer a research-related injury, or have questions, concerns or complaints about the study, please contact the investigator, [Insert investigator Name].

If you have questions about your rights as a study subject, or if you have questions, concerns, or complaints about the research, you may contact:

Western Institutional Review Board® (WIRB®)
1019 39th Avenue SE Suite 120
Puyallup, Washington  98374-2115
Telephone:  1-800-562-4789 or 360-252-2500
E-mail: Help@wirb.com

WIRB is a group of people who perform independent review of research.

WIRB will not be able to answer some study-specific questions, such as questions about appointment times. However, you may contact WIRB if the research staff cannot be reached or if you wish to talk to someone other than the research staff.

**CONSENT**

I have read and understand this consent form. All my questions regarding participation in this research study have been answered. I or my parent/guardian will receive a copy of the consent form that was used during the consent process to keep for future reference. I do not give up any of my legal rights as a research subject by signing this form.

I voluntarily agree to participate in this study.

**Consent and Assent Instructions:**

**Consent:** Subjects 18 years and older must sign on the subject line below
For subjects under 18, consent is provided by the parent or guardian

**Assent:** Written assent is required for subjects ages 16 and 17 years using the Assent section below.

_________________________________________________
Printed Name of Subject

_________________________________________________ __________________
Signature of Subject  Date
Printed Name of Subject’s Parent/Guardian
(If applicable)

______________________________ __________________
Signature of Subject’s Parent/Guardian Date
(If applicable)

Printed Name of Individual Conducting Consent Procedure

______________________________ __________________
Signature of Individual Conducting Consent Procedure Date

Subject ID: ________________

Assent for ages 16 and 17:

______________________________
Subject’s Name

__________________________
Subject’s Signature for Assent Date Age (years)

Statement of Parent or Guardian:

My child appears to understand the research to the best of his or her ability and has agreed to participate.

__________________________
Signature of Parent or Guardian Date
**ASSENT SECTION:**
Statement of person conducting assent discussion:

- I have explained all aspects of the research to the subject to the best of his or her ability to understand.
- I have answered all the questions of the subject relating to this research.
- The subject agrees to be in the research.
- I believe the subject’s decision to enroll is voluntary.
- The study doctor and study staff agree to respect the subject’s physical or emotional dissent at any time during this research when that dissent pertains to anything being done solely for the purpose of this research.

________________________________________ __________________
Signature of Person Conducting   Date
Assent Discussion